42
Discover us

4 December 2024

In a recent interview with Heping Xu and Mei Chen, Professors at the Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences at Queen’s University Belfast, we had the opportunity to gain valuable insights into their collaboration with Boehringer Ingelheim and how opnMe has advanced their research in retinal disease.

54
Collaborate with us

02 December 2024

Cancers represent complex ecosystems that include tumor cells and a variety of non-cancerous cells such as immune cells, stroma cells, and other cell types present in the surrounding tissues, all embedded in a modified extracellular matrix. This environment within and around the tumor is known as the tumor microenvironment (TME).

68
Discover us

25 November 2024

Watch the recorded session of our opnMe online seminar from November 14, 2024, to discover how the selective Cathepsin C (CatC) inhibitor, BI-9740, from opnMe has helped elucidate new roles of CatC signaling in immune response and cardiovascular disease.

51
Discover us

5 November 2024

We recently had the chance to speak to Laura-Marie Zimmermann, a former postdoctoral researcher at the University Hospital Cologne, about her experience with opnMe and her interaction with scientists from Boehringer Ingelheim.

46
Discover us

28 October 2024

Christian Wolfrum, VP of Research and Professor at the Department of Health Sciences and Technology at ETH Zurich, shared his collaboration experience with Boehringer Ingelheim, enabled through an opn2EXPERTS question on opnMe.

Discover us

Hear from our collaborators

slide 1 to 2 of 13